.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG11_Anifrolumab.Anifrolumab

Information

Anifrolumab is a fully human monoclonal antibody that targets the type I interferon receptor subunit 1 (IFNAR1), blocking activity of type I interferons implicated in the pathogenesis of systemic lupus erythematosus (SLE). It is approved for the treatment of moderate to severe SLE in adults who are receiving standard therapy.

Pharmacokinetics

Population pharmacokinetics reported in adult SLE patients (including males and females) after intravenous administration.

References

1. Almquist, J, et al., & Chia, YL (2022). Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus. Journal of clinical pharmacology 62(9) 1106–1120. DOI:10.1002/jcph.2055 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35383948

2. Tang, W, et al., & MacDonald, A (2023). Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics 62(5) 655–671. DOI:10.1007/s40262-023-01238-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37148484

3. Chia, YL, et al., & Morand, EF (2022). Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology (Oxford, England) 61(5) 1900–1910. DOI:10.1093/rheumatology/keab704 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34528084

Revisions

• 06/2025 initial generated model